Highlights of This Issue 4975

SPECIAL FEATURES
Editorial
4977 AACR Cancer Progress Report 2014: Transforming Lives Through Research
Jesse Potash and Kenneth C. Anderson

Policy Statement
4978 Reliable and Effective Diagnostics Are Keys to Accelerating Personalized Cancer Medicine and Transforming Cancer Care: A Policy Statement from the American Association for Cancer Research
Charles L. Sawyers and Laura J. van ’t Veer

CCR Translations
4982 The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
Antoni Ribas and Paul C. Tumeh
See related article, p. 5064

CCR New Strategies
4985 New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach
Amer M. Zeidan and Steven D. Gore

CCR Perspectives in Drug Approval
4994 FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAF V600E Mutation
Geoffrey Kim, Amy E. McKee, Yang-Min Ning, Maitreyee Hazarika, Marc Theoet, John R. Johnson, Qiang Casey Xu, Shenghui Tang, Rajeshwari Sridhara, Xiaoping Jiang, Kun He, Donna Roscoe, W. David McGuinn, Whitney S. Helms, Anne Marie Russell, Sarah Pope Mikinski, Jeanne Fourie Zirkelbach, Justin Earp, Qi Liu, Amna Ibrahim, Robert Justice, and Richard Pazdur

Molecular Pathways
5001 Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination
Teresa Ezponda and Jonathan D. Licht

CANCER THERAPY: CLINICAL
5009 A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer

5023 Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

5032 Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
Toshio Shimizu, Patricia M. LoRusso, Kyri P. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon S. Smith, Drew W. Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert Laliberte, Maurizio Voi, and Anthony W. Tolcher
Table of Contents

PERSONALIZED MEDICINE AND IMAGING
5052 Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Yoshihiro Obue, Koji Kurose, Yu Mizote, Hirofumi Matsumoto, Yumi Nishio, Midori Isobe, Minoru Fukuda, Akiko Uenaka, Mikio Oka, and Eiichi Nakayama

ASSOCIATION OF PD-1, PD-1 Ligands, AND OTHER FEATURES OF THE TUMOR IMMUNE MICROENVIRONMENT WITH RESPONSE TO ANTI–PD-1 THERAPY
Janis M. Taube, Alison Klein, Julie R. Brahmer, Haiying Xu, Xiaoyu Pan, Jung H. Kim, Lieping Chen, Drew M. Pardoll, Suzanne L. Topalian, and Robert A. Anders
See related commentary, p. 4982

CANCER THERAPY: PRECLINICAL
5075 Anti-CCR4 Monoclonal Antibody Mogamulizumab for the Treatment of EBV-Associated T- and NK-Cell Lymphoproliferative Diseases
Tetsuhiro Kanazawa, Yutaka Hiramatsu, Seiko Iwata, Mohammed Siddiquey, Yoshitaka Sato, Michio Suzuki, Yoshinori Ito, Fumi Goshima, Takayuki Murata, and Hiroshi Kimura

5085 Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
David Karnak, Carl G. Engelke, Leslie A. Parsels, Tanseem Kausar, Dongping Wei, Jordan R. Robertson, Katherine B. Marsh, Mary A. Davis, Lili Zhao, Jonathan Maybaum, Theodore S. Lawrence, and Meredith A. Morgan

5097 Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma
Audrey Lamora, Julie Talbot, Gwenoia Bougras, Jérôme Amiaud, Marion Leduc, Julie Chesneau, Julien Taurelle, Verena Stresing, Marie Cécile Le Deley, Marie Françoise Heymann, Dominique Heymann, Françoise Redini, and Franck Verrecchia

BIOLOGY OF HUMAN TUMORS
5113 Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
Chi Young Ok, Jiayu Chen, Zijian Y. Xu-Monette, Alexandar Tzankov, Ganrajra C. Manyam, Ling Li, Carlo Visco, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W.L. Choi, J. Han van Krieken, Jooyung Huh, Xiaoying Zhao, Maurilio Ponzoni, Andrés J.M. Ferreri, Francesco Bertoni, John F. Farnen, Michael B. Möller, Miguel A. Piris, Jane N. Winter, L. Jeffrey Medeiros, and Ken H. Young

5124 Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival
Snehal Dabir, Amy Kluge, Adam Kresak, Michael Yang, Pingfu Fu, Bernd Groner, Gary Wilday, and Afshin Dowlati

5133 The Prostate Cancer Susceptibility Variant rs2735839 Near KLF3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients
Yonggang He, Jian Gu, Sara Strom, Christopher J. Logothetis, Jeri Kim, and Xifeng Wu

LETTERS TO THE EDITOR
5140 Tumor Stromal Phenotypes Define VEGF Sensitivity—Letter
Tumor Stromal Phenotypes Define VEGF Sensitivity—Response

Correction: A Severe Combined Immunodeficient–hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma

About the Cover
The cover shows acetylated histone H3 immunohistochemistry staining of skin biopsy at half an hour after the fifth doses of CUDC-101 treatment in the 275-mg/m$^2$ cohort. CUDC-101 induces the accumulation of acetylated histone H3. For details, see the article by Shimizu and colleagues on page 5032 of this issue.